Janssen-Cilag's Simponi (golimumab) has been granted an extension of indication by the Therapeutic Goods Administration to include the treatment of adults with active non-radiographic axial spondyloarthritis (nr-Axial SpA) under certain conditions.
Biogen's Alprolix (eftrenonacog alfa) has also had its indication extended to include "use in children 12 years of age or under with haemophilia B".
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Sep 16